Board Changes

08 May 2014


Frontier IP Group plc
("Frontier IP" or "the Company")

Frontier IP, which specialises in the commercialisation of university intellectual property, is pleased to announce the appointment of Dr Campbell Wilson as a non-executive Director with immediate effect.

Campbell, who is Chair of the UK Pharmaceutical Licensing Group, has worked in the UK pharmaceutical industry for approximately 35 years. The last 17 years of his career were in business development at AstraZeneca, the global research-based biopharmaceutical company, latterly as Executive Business Development Director within the company's central Business Development function. He led strategic collaboration and licensing activities at the unit, driving multiple technology and oncology therapy area collaborations and product licensing deals, including high profile and innovative agreements.

Before his involvement in business development, Campbell worked in senior level scientific roles in cardiovascular drug discovery at AstraZeneca, and earlier at Beecham Pharmaceuticals (now GSK).
Campbell holds a PhD in Cardiovascular Pharmacology and has lectured and published extensively over his career. As well as chairing the UK Pharmaceutical Licensing Group, he participates in the European Pharma Licensing Council and is a consultant to Medius Associates Limited, the pharmaceutical and healthcare consultancy.

At the same time, Frontier IP also announces that Marcus Yeoman, Non-Executive Director, is today retiring from the Board. The Board would like to thank Marcus for his contribution and wishes him well for the future.

Neil Crabb, Chief Executive of Frontier IP, said,

"We are delighted to welcome Campbell Wilson to the Board. Campbell has some 35 years' experience in the global pharmaceutical industry with experience in both scientific and business development roles at a senior level. His long and successful track record in negotiating and forming strategic collaborations and licensing agreements is directly relevant to our business and will be of particular significance as we progress our work with University of Dundee to establish a funding vehicle for its Drug Discovery Unit."
At the same time as welcoming Campbell, I would also like to thank Marcus Yeoman, who leaves today, for his contribution to Frontier IP during his time on the Board."

Campbell Wilson added,

"I am delighted to be joining the Board of Frontier IP, particularly as the Company is entering such an interesting period in its growth. I look forward to bringing my experience in both drug discovery and business development to the Company and its university relationships. I hope to make a significant contribution to Frontier IP's partnerships as we assist them in maximising the commercial value of the technologies they have created."


Disclosures required pursuant to Rule 17 or paragraph (g) of Schedule Two of the AIM Rules for Companies

Dr Campbell Wilson, aged 59 years, is currently a director of the following companies and organisations:

Pharmaceutical Licensing Group Limited

Self-employed (sole trader) as Wilson BioPharma Consulting

There is no further information to be disclosed under Rule 17 or paragraph (g) of Schedule Two of the AIM Rules for Companies.

Frontier IP Group Plc
0131 240 1251
Neil Crabb, Chief Executive
Company website:

Cantor Fitzgerald Europe
(Nominated Adviser and Joint Broker)
020 7894 7000
Mark Percy / Catherine Leftley, Corporate Finance
David Banks / Paul Jewell, Corporate Broking

Peterhouse Corporate Finance Limited
(Joint Broker)
020 7469 0935
Jon Levinson / Lucy Williams

KTZ Communications
020 3178 6378
Katie Tzouliadis / Deborah Walter

Notes to Editor:

Frontier IP specialises in the commercialisation of Intellectual Property. It establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and helps to maximise the commercial value of technologies emerging from their research programmes.